Introduction
============

Lung cancer was the most commonly diagnosed cancer as well as the leading cause of cancer death in males globally, and it was the fourth most commonly diagnosed cancer and the second leading cause of cancer death among females in 2008.[@b1-ott-8-2875] In the United States, there were about 228,190 estimated new lung cancer cases and 159,480 estimated deaths in 2013.[@b2-ott-8-2875] In the People's Republic of China, lung cancer increased 465% during the past 30 years and became the leading cause of cancer death in the current decade. It is estimated that over one million Chinese will be diagnosed with lung cancer by the year 2025.[@b3-ott-8-2875]

Lung cancer has been considered as a disease determined solely by environmental exposure, such as exposure to cigarette smoke and asbestos.[@b4-ott-8-2875],[@b5-ott-8-2875] However, only a small proportion of persons who are exposed to such risk factors will develop lung cancer, which suggests that an individual's susceptibility might contribute to lung cancer risk. Recently, more and more results have supported the hypothesis that common genetic variations of drug-metabolizing enzyme genes may be of importance in determining an individual's sensitivity to develop lung cancer.[@b6-ott-8-2875]

Glutathione S-transferase theta-1 (GSTT1), a member of glutathione S-transferases (GSTs), is a kind of phase II detoxification enzyme that is involved in detoxifying several kinds of carcinogens such as benzo(a)pyrene present in tobacco smoke.[@b7-ott-8-2875],[@b8-ott-8-2875] *GSTT1* deletion polymorphism is known to abolish enzyme activities and modulate lung cancer risk.[@b9-ott-8-2875] Lan et al,[@b10-ott-8-2875] for the first time, explored the association of *GSTT1* deletion polymorphism with lung cancer risk in the Chinese population in 1999. After that, a series of epidemiological studies investigated this association in the Chinese population,[@b11-ott-8-2875]--[@b30-ott-8-2875] successively. However, the conclusions by previous studies remained controversial rather than conclusive. This urged us to perform this meta-analysis using the updated data, which aims at deriving a precise estimate of *GSTT1* deletion polymorphism associated with lung cancer risk among Chinese population.

Materials and methods
=====================

Literature source and analytical methods
----------------------------------------

Systematic searches were conducted through the databases of Medline/PubMed, Embase, Web of Science, Wanfang Med Online, and Chinese National Knowledge Infrastructure, with the following keywords: "lung cancer" or "lung neoplasm" or "lung carcinoma" and "*GSTT1*" or "glutathione S-transferase T1" and "polymorphism" and "Chinese" or "China." The starting date for searched publications was January 1, 1990 and the ending date of searched publications was January 31, 2015. We also searched the reference list of relevant publications to identify additional studies manually.

Criteria for inclusion: 1) the subjects of study must be Chinese; 2) papers should include *GSTT1* deletion polymorphism and lung cancer risk; 3) case--control study and cohort study; and 4) complete data on genotype of *GSTT1* deletion polymorphism for calculating odds ratio (OR) with 95% confidence intervals (95% CI). Accordingly, reviews and repeated or overlapping literatures were excluded. If studies contained overlapping cases and/or controls, the latest publication including more information was preferred. We only included journal articles, and not dissertations.

In total, 38 published studies were identified which studied the association between *GSTT1* deletion polymorphism and lung cancer risk among Chinese population. We reviewed all papers in accordance with the aforementioned criteria defined and excluded 5 dissertations, 4 reviews,[@b31-ott-8-2875]--[@b34-ott-8-2875] and 9 overlapping articles.[@b10-ott-8-2875],[@b35-ott-8-2875]--[@b42-ott-8-2875] Therefore, 20 studies were selected for our study.

Data extraction
---------------

Data were extracted and tabulated first, and then inputted into an electronic database. The following information was extracted from each study: authors' names, year of publication, area, source of control, number of cases and controls, genotype frequency, and stratified factors. Characteristics of individual studies are summarized in [Table 1](#t1-ott-8-2875){ref-type="table"}.

Quantitative data synthesis
---------------------------

A meta-analysis was conducted to evaluate the relationship between *GSTT1* deletion polymorphism and lung cancer risk among Chinese population. The heterogeneity was assessed by Cochrane *Q* statistics test.[@b43-ott-8-2875] Data were combined using either a fixed-effects model or a random-effects model depending on the results of heterogeneity test. A fixed-effects model is used when there is no heterogeneity, while a random-effects model is used when heterogeneity exists.[@b43-ott-8-2875] Cumulative meta-analysis was performed to investigate the tendency of results by accumulating single study year by year.[@b44-ott-8-2875] Funnel plot was drawn to evaluate the publication bias. Egger's test (an adjusted rank correlation test is proposed as a technique for identifying publication bias)[@b45-ott-8-2875] and Begg's test (a linear regression approach is used to measure funnel plot asymmetry on the natural logarithm scale of the OR)[@b46-ott-8-2875] were applied to assess the symmetry of funnel plot. Sensitivity analysis was performed by deleting one study each time.[@b44-ott-8-2875]

All of the statistical analyses were performed using Review Manager (Version 5.0.24, The Cochrane Collaboration) and STATA 10.0 software package (Stata Corporation, College Station, TX, USA). All the tests were two-sided; a *P*-value of 0.05 for any test or model was considered to be statistically significant.

Results
=======

Meta-analysis databases
-----------------------

A database was created according to the extracted information from selected articles. Some essential information is listed in [Table 1](#t1-ott-8-2875){ref-type="table"}. It indicates the study (first author et al), year of publication, area, source of control, number of cases and controls, and stratified factors. There were a total of 20 studies, with 3,351 cases and 4,683 controls concerning the association of *GSTT1* deletion polymorphism with lung cancer risk among Chinese population. The frequency of *GSTT1* null genotype was 53.4% and 48.0% in cases and controls, respectively.

Test of heterogeneity
---------------------

[Table 2](#t2-ott-8-2875){ref-type="table"} shows the association between *GSTT1* deletion polymorphism and lung cancer risk among Chinese population. Our results showed that there was no heterogeneity for *GSTT1* null genotype versus present genotype in the subgroup analyses of squamous cell carcinoma and adenocarcinoma. Therefore, we calculated the summary ORs for them with a fixed-effects model. Random-effects model was used to calculate the summary ORs for the rest.

Quantitative data synthesis
---------------------------

[Table 2](#t2-ott-8-2875){ref-type="table"} listed the summary ORs of the association between *GSTT1* deletion polymorphism and lung cancer risk among Chinese population on the basis of 3,351 cases and 4,683 controls. Overall, there was a statistically significant correlation of *GSTT1* null genotype with an increased lung cancer risk among Chinese population, and the summary OR was 1.31 (95% CI: 1.12--1.52; [Figure 1](#f1-ott-8-2875){ref-type="fig"}). The cumulative meta-analysis accumulated the studies according to the year of publications, which may determine whether new studies are needed or not. Our results showed that there was still a significant association between *GSTT1* deletion polymorphism and lung cancer risk among Chinese population; the cumulative OR was 1.31 with 95% CI: 1.12--1.52 ([Figure 2](#f2-ott-8-2875){ref-type="fig"}).

In subgroup analysis for source of control, we observed an increased risk of lung cancer among subjects carrying *GSTT1* null genotype compared with those carrying present genotype in healthy subjects-based controls (OR =1.31, 95% CI: 1.11--1.55), but not in hospitalized patient-based controls (OR =1.28, 95% CI: 0.89--1.83). We observed an increased risk of lung squamous cell carcinoma and lung adenocarcinoma among subjects carrying *GSTT1* null genotype compared with those carrying present genotype in stratified analysis by histological subtype (OR =2.29, 95% CI: 1.84--2.85 and OR =1.47, 95% CI: 1.22--1.77, respectively). We did not observe any association between *GSTT1* null genotype and lung cancer risk stratified by smoking status (OR =1.54, 95% CI: 0.97--2.43 for smokers and OR=1.03, 95% CI: 0.70--1.51 for nonsmokers, respectively; [Table 2](#t2-ott-8-2875){ref-type="table"}).

Bias diagnosis
--------------

Publication bias was examined by using funnel plot analysis. The shape of the funnel plot seemed to be approximately symmetrical ([Figure 3](#f3-ott-8-2875){ref-type="fig"}). Both Egger's test and Begg's test suggested that publication bias might have few effects on the summary estimates, except for the subgroup analysis of squamous cell carcinoma, owing to *P*-value being equal to 0.024 in Begg's test.

Sensitivity analysis
--------------------

We performed a sensitivity analysis to determine the influence of individual dataset on the summary OR by consecutively deleting individual studies. The combined OR was not significantly altered by deleting each selected study sequentially, which indicated that our results were stable and robust ([Figure 4](#f4-ott-8-2875){ref-type="fig"}).

Discussion
==========

*GSTT1* gene is mapped on chromosome 22q11.23. It is 8,146 bp in length, consisting of five exons and four introns, which encodes a cytoplasmic protein of 240 amino acid residues with a molecular weight of 28-kDa. *GSTT1* gene has a functional and nonfunctional allele. Homozygosity for the nonfunctional allele of *GSTT1* (null genotype) gene causes an absence of GSTT1 enzyme activity.[@b47-ott-8-2875] Individuals who carry homozygous deletions in this gene are thought to be at increased risks for malignancies.[@b8-ott-8-2875] Studies have shown that the *GSTT1* gene deletion have effects on survival and clinical outcomes of lung cancer patients. Ruano-Ravina et al[@b48-ott-8-2875] reported that lung cancer patients with deleted *GSTT1* genotype had a significantly shorter survival than those with present *GSTT1* genotype. Sreeja et al[@b49-ott-8-2875] reported that the *GSTT1* −/− genotype along with stage was significantly associated with overall survival and was found to be an independent prognostic factor for shorter lung cancer survival. Gonlugur et al's[@b50-ott-8-2875] study showed that none of the patients with *GSTT1* null genotype, but 30% of the patients with *GSTT1*-positive genotype had liver metastasis among 81 lung cancer patients.[@b50-ott-8-2875]

Several meta-analyses explored the association of *GSTT1* null genotype with the development of several kinds of cancers among Chinese population.[@b51-ott-8-2875]--[@b57-ott-8-2875] In this paper, we performed a systematic literature review to comprehensively evaluate the association of *GSTT1* deletion polymorphism with lung cancer risk among Chinese population. We also evaluated the possible effect modifications by source of control, smoking status, and histological subtype. In summary, we observed an increased lung cancer risk among Chinese population with *GSTT1* null genotype compared with those carrying present genotype. To our knowledge, four published papers have addressed the association between *GSTT1* deletion polymorphism and lung cancer risk among Chinese population. However, the conclusions are mixed, for example, three previous meta-analyses observed a positive association between *GSTT1* null genotype and an increased lung cancer risk among Chinese population,[@b31-ott-8-2875],[@b33-ott-8-2875],[@b34-ott-8-2875] but one not.[@b32-ott-8-2875] Furthermore, there are several key limitations in all four previous meta-analyses. Namely, one eligible paper[@b14-ott-8-2875] published before 2010 was not included in Wang et al's paper;[@b34-ott-8-2875] two eligible papers[@b13-ott-8-2875],[@b25-ott-8-2875] published before 2013 were not included in Liu et al's paper[@b32-ott-8-2875] and Gui et al's paper.[@b31-ott-8-2875] Moreover, the number of cases and controls reported by Gui et al[@b31-ott-8-2875] for Chan-Yeung et al's study[@b12-ott-8-2875] did not seem in line with the data in Chan-Yeung et al's original publication;[@b12-ott-8-2875] for Liu et al's paper,[@b33-ott-8-2875] two overlapping papers[@b10-ott-8-2875],[@b37-ott-8-2875] were not excluded and two eligible papers[@b13-ott-8-2875],[@b40-ott-8-2875] published before 2013 were not included. Therefore, the conclusions from them are not entirely reliable. Our cumulative meta-analysis included 20 selected studies, with 3,351 cases and 4,683 controls on the basis of the updated data. We believed that this current meta-analysis presented a precise estimate of the association between *GSTT1* deletion polymorphism and lung cancer risk among Chinese population.

Cigarette smoke is an evident risk factor for lung cancer, and *GSTT1* gene is involved in metabolizing various carcinogens present in cigarette smoke. To address the effect of cigarette smoke on the correlation of *GSTT1* deletion polymorphism with lung cancer risk, subgroup analysis was conducted in the light of smoking status. We did not observe any association of *GSTT1* null genotype with increased risk of lung cancer among smokers or nonsmokers, which might be owing to the relatively small sample size (680 cases in smokers and 636 cases in nonsmokers).

To our knowledge, lung cancer consists of at least three major histological subtypes: squamous cell carcinoma, adenocarcinoma, and small-cell carcinoma. Studies have shown that the development of squamous cell carcinoma and small-cell carcinoma is more often attributed to cigarette smoking, whereas adenocarcinoma is more weakly associated with cigarette smoking than those two subtypes, indicating there is a difference in carcinogenic processes among different histological subtypes of lung cancer.[@b58-ott-8-2875] Therefore, a subgroup analysis was performed according to histological subtype. We observed a statistically significant association of *GSTT1* deletion polymorphism with an increased risk of squamous cell carcinoma and adenocarcinoma. We did not perform subgroup analysis in additional histological subtypes, since the sample size for those was relatively small.

There are some potential limitations inherent in this meta-analysis. First, only published articles were included in this study, which may cause publication bias. To address this issue, both Egger's test and Begg's test were applied in this study. Our results demonstrated that the likelihood of key publication bias was negligible in this current meta-analysis. Second, although some confounders were matched perfectly between cases and controls for each study at the beginning of study design, different study might have different eligibility criteria for subjects and different source of controls, which should be considered when expounding the combined effects. When the subgroup analysis was conducted by source of control, the association with *GSTT1* null genotype was much stronger in the conducted analysis of studies including healthy subjects as controls (OR =1.31, 95% CI: 1.11--1.55) than that of studies including hospitalized patients controls (OR =1.28, 95% CI: 0.89--1.83), indicating that the distribution frequency of *GSTT1* null genotype in the hospitalized patients-based control groups might not be representative of the general population. Third, this meta-analysis is based on an unadjusted estimate; thus, a more precise analysis depending on adjusted factors should be conducted in the future study.

In summary, this meta-analysis found that *GSTT1* null genotype was associated with an increased risk of lung cancer among Chinese population. Studies with larger sample size are required to evaluate gene--gene and gene--environment interactions on *GSTT1* deletion polymorphism and lung cancer risk among Chinese population further.
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###### 

General information of selected studies in this meta-analysis

  Study                               Area             Source of control       Number of cases   Number of controls   Stratified factors
  ----------------------------------- ---------------- ----------------------- ----------------- -------------------- ----------------------------------
  Cao et al[@b11-ott-8-2875]          Hunan            Healthy subjects        104               205                  Histological type
  Chan-Yeung et al[@b12-ott-8-2875]   Hong Kong        Healthy subjects        229               197                  
  Fowke et al[@b13-ott-8-2875]        Shanghai         Healthy subjects        208               784                  
  He and Chan[@b14-ott-8-2875]        Yunnan           Healthy subjects        61                46                   
  Jiang et al[@b15-ott-8-2875]        Inner Mongalia   Healthy subjects        322               456                  Smoke
  Lan et al[@b16-ott-8-2875]          Yunnan           Healthy subjects        122               122                  
  Liang et al[@b17-ott-8-2875]        Jiangsu          Hospitalized patients   152               152                  Histological type
  Liang et al[@b18-ott-8-2875]        Guangxi          Hospitalized patients   68                70                   
  Liu et al[@b19-ott-8-2875]          Jilin            Healthy subjects        100               135                  Smoke
  London et al[@b20-ott-8-2875]       Shanghai         Healthy subjects        232               710                  
  Ma et al[@b21-ott-8-2875]           Sichuan          Healthy subjects        125               125                  Sex
  Pan et al[@b22-ott-8-2875]          Jiangxi          Hospitalized patients   523               523                  Smoke, histological type and sex
  Qi et al[@b23-ott-8-2875]           Gansu            Hospitalized patients   53                72                   Smoke, histological type and age
  Wang et al[@b24-ott-8-2875]         Beijing          Hospitalized patients   112               119                  Smoke
  Wang et al[@b25-ott-8-2875]         Henan            Healthy subjects        77                107                  Histological type
  Wang et al[@b26-ott-8-2875]         Henan            Healthy subjects        209               256                  
  Yuan et al[@b27-ott-8-2875]         Sichuan          Healthy subjects        150               152                  Smoke and histological type
  Zhang et al[@b28-ott-8-2875]        Yunnan           Healthy subjects        110               100                  
  Zhang et al[@b29-ott-8-2875]        Guangdong        Healthy subjects        161               165                  Smoke, histological type and sex
  Zhao et al[@b30-ott-8-2875]         Singapore        Hospitalized patients   233               187                  

###### 

Combined ORs on the relation of the *GSTT1* deletion polymorphism to lung cancer risk among Chinese population

  Null versus present                  Cases/controls   Heterogeneity test   Combined OR (95% CI)   Hypothesis test     *df*   Begg's test   Egger's test                         
  ------------------------------------ ---------------- -------------------- ---------------------- ------------------- ------ ------------- -------------- ------ ------- ------ -------
  Total                                3,351/4,683      46.23                0.0005                 1.31 (1.12--1.52)   3.44   0.0006        19             0.23   0.820   0.56   0.586
  Stratified by source of control                                                                                                                                                 
   Healthy subjects                    2,210/3,560      27.75                0.01                   1.31 (1.11--1.55)   3.14   0.02          13             1.09   0.274   1.51   0.156
   Hospitalized patients               1,141/1,123      18.13                0.003                  1.28 (0.89--1.83)   1.34   0.18          5              0.38   0.707   0.44   0.683
  Stratified by smoking status                                                                                                                                                    
   Smokers                             680/673          18.09                0.003                  1.54 (0.97--2.43)   1.84   0.07          5              0.00   1.000   0.45   0.674
   Nonsmokers                          636/884          15.45                0.02                   1.03 (0.70--1.51)   0.14   0.89          6              0.75   0.452   1.10   0.334
  Stratified by histological subtype                                                                                                                                              
   Squamous cell carcinoma             520/1,113        8.66                 0.12                   2.29 (1.84--2.85)   7.45   \<0.00001     5              2.25   0.024   2.59   0.061
   Adenocarcinoma                      691/1,350        4.36                 0.63                   1.47 (1.22--1.77)   4.03   0.0001        6              1.20   0.230   1.46   0.205

**Abbreviations:** OR, odds ratio; *GSTT1*, glutathione S-transferase T1; CI, confidence interval.
